This website uses cookies to keep track of login sessions and for internal Piwik Statistics. See our Legal Notes for details. This website uses cookies, learn more

PFIZi009-A

RCi188

iPSC line

In Stock
At European Collection of Authenticated Cell Cultures (ECACC)
Timepoint: Confluency
Magnification: x4
Timepoint: Confluency
Magnification: x10
Timepoint: 48hr post thaw
Magnification: x4
Timepoint: 48hr post thaw
Magnification: x10
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line
hPSCreg Name PFIZi009-A
Alternative name(s)
RCi188
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines

Provider
Depositor Pfizer Limited - Pfizer (PFIZ)
Distributors
EBiSC
European Collection of Authenticated Cell Cultures (ECACC)

External Databases
hPSCreg PFIZi009-A
BioSamples SAMEA4085222
ECACC 66540164
Cellosaurus CVCL_RG04
CLO CLO_0101587
Wikidata Q54947261

General Information
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information#

General Donor Information
Sex female
Age of donor (at collection) 25-29

Phenotype and Disease related information (Donor)
Diseases A disease was diagnosed.
Dravet syndrome
Dravet syndrome in the OLS
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • SMEI
  • Severe myoclonus epilepsy of infancy
  • Severe myoclonic epilepsy of infancy
Genetic variants
SCN1A (target)
2q24.3
NM_006920.4:c.314C>T
Heterozygous
SCV000242702.10
Transition C > T, Nucleotide position 314, codon 105, Amino Acid Change Threonine > Isoleucine, Variant Type: heterozygous

External Databases (Donor)
BioSamples SAMEA4085220

hIPSC Derivation#

General
Source cell type
erythroblast
erythroblast in the OLS
A nucleated precursor of an erythrocyte that lacks hematopoietic lineage markers.
Age of donor (at collection) 25-29

Reprogramming method
Vector type Non-integrating
Vector Sendai virus
Genes

Vector free reprogramming

Other
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Latest released batch
Culture medium Essential 8
Passage method EDTA
Surface coating Geltrex / Matrigel
O2 concentration 21
CO2 concentration 5
Temperature 37
The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium Essential 8™

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SSEA-4
Yes
TRA 1-60
Yes
SSEA-1
No
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
CXCR4
Yes
GATA6
Yes
SOX17
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
VIM
Yes
NCAM1
Yes
MIXL1
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
NeuroD1
Yes
HES5
Yes
PAX6
Yes

Microbiology / Virus Screening
HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Sterility
Inoculation for microbiological growth No Contaminants Detected
Mycoplasma Not Detected
Viability Viable post-cryopreservation

Genotyping#

Karyotyping (Cell Line)
Has the cell line karyotype been analysed?
Yes
46,XX
Passage number: 17
Karyotyping method: G-Banding

Other Genotyping (Cell Line)